Literature DB >> 19652947

Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa.

Fabio Ferrari1, Qin Lu, Cassio Girardi, Olivier Petitjean, Charles-Hugo Marquette, Frederic Wallet, Jean-Jacques Rouby.   

Abstract

PURPOSE: Ventilator-associated pneumonia caused by Pseudomonas aeruginosa with impaired sensitivity to ceftazidime is frequent in critically ill patients. The aim of the study was to compare lung tissue deposition and antibacterial efficiency between nebulized and intravenous administrations of ceftazidime in ventilated piglets with pneumonia caused by Pseudomonas aeruginosa with impaired sensitivity to ceftazidime.
METHODS: Ceftazidime was administered 24 h following the intra-bronchial inoculation of Pseudomonas aeruginosa (minimum inhibitory concentration = 16 microg ml(-1)), either by nebulization (25 mg kg(-1) every 3 h, n = 6) or by continuous intravenous infusion (90 mg kg(-1) over 24 h after an initial rapid infusion of 30 mg kg(-1), n = 6). Four non-treated inoculated animals served as controls. All piglets were killed 48 h (intravenous and control groups) or 51 h (aerosol group) after inoculation. Lung tissue concentrations and lung bacterial burden were assessed on multiple post-mortem sub-pleural lung specimens [(lower limit of quantitation = 10(2) colony forming unit (cfu g(-1))].
RESULTS: Ceftazidime trough lung tissue concentrations following nebulization were greater than steady-state lung tissue concentrations following continuous intravenous infusion [median and interquartile range, 24.8 (12.6-59.6) microg g(-1) vs. 6.1 (4.6-10.8) microg g(-1)] (p < 0.001). After 24 h of ceftazidime administration, 83% of pulmonary segments had bacterial counts <10(2) cfu g(-1) following nebulization and only 30% following intravenous administration (p < 0.001). In control animals, 10% of lung segments had bacterial counts <10(2) cfu g(-1) 48 h following bronchial inoculation.
CONCLUSION: Nebulized ceftazidime provides more efficient bacterial killing in ventilated piglets with pneumonia caused by Pseudomonas aeruginosa with impaired sensitivity to ceftazidime.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19652947     DOI: 10.1007/s00134-009-1605-2

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  38 in total

1.  Mechanical ventilation-induced air-space enlargement during experimental pneumonia in piglets.

Authors:  I Goldstein; M T Bughalo; C H Marquette; G Lenaour; Q Lu; J J Rouby
Journal:  Am J Respir Crit Care Med       Date:  2001-03       Impact factor: 21.405

Review 2.  Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options.

Authors:  Marilee D Obritsch; Douglas N Fish; Robert MacLaren; Rose Jung
Journal:  Pharmacotherapy       Date:  2005-10       Impact factor: 4.705

3.  Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs.

Authors:  Ivan Goldstein; Frederic Wallet; Jerome Robert; Marie-Helene Becquemin; Charles-Hugo Marquette; Jean-Jacques Rouby
Journal:  Am J Respir Crit Care Med       Date:  2002-01-15       Impact factor: 21.405

4.  Lung deposition of continuous and intermittent intravenous ceftazidime in experimental Pseudomonas aeruginosa bronchopneumonia.

Authors:  Cassio Girardi; Marc Tonnellier; Ivan Goldstein; Alfonso Sartorius; Frederic Wallet; Jean-Jacques Rouby
Journal:  Intensive Care Med       Date:  2006-07-21       Impact factor: 17.440

5.  Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model.

Authors:  Luis Alou; Lorenzo Aguilar; David Sevillano; María-José Giménez; Olatz Echeverría; María-Luisa Gómez-Lus; José Prieto
Journal:  J Antimicrob Chemother       Date:  2005-01-13       Impact factor: 5.790

6.  Concentrations of cefpodoxime in serum and bronchial mucosal biopsies.

Authors:  D R Baldwin; R Wise; J M Andrews; D Honeybourne
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

7.  Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002.

Authors:  Robert K Flamm; Mellany K Weaver; Clyde Thornsberry; Mark E Jones; James A Karlowsky; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

8.  Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects.

Authors:  J J Rouby; E Martin De Lassale; P Poete; M H Nicolas; L Bodin; V Jarlier; Y Le Charpentier; J Grosset; P Viars
Journal:  Am Rev Respir Dis       Date:  1992-10

9.  Pseudomonas aeruginosa carriage, colonization, and infection in ICU patients.

Authors:  Antonella Agodi; Martina Barchitta; Rosalba Cipresso; Loredana Giaquinta; Maria Antonietta Romeo; Carmelo Denaro
Journal:  Intensive Care Med       Date:  2007-05-15       Impact factor: 17.440

10.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee.

Authors:  J L Vincent; D J Bihari; P M Suter; H A Bruining; J White; M H Nicolas-Chanoin; M Wolff; R C Spencer; M Hemmer
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

View more
  16 in total

1.  BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia.

Authors:  Michael S Niederman; Jean Chastre; Kevin Corkery; James B Fink; Charles-Edouard Luyt; Miguel Sánchez García
Journal:  Intensive Care Med       Date:  2011-12-07       Impact factor: 17.440

2.  Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa.

Authors:  Qin Lu; Cassio Girardi; Mao Zhang; Belaïd Bouhemad; Kamel Louchahi; Olivier Petitjean; Frédéric Wallet; Marie-Helene Becquemin; Gilles Le Naour; Charles-Hugo Marquette; Jean-Jacques Rouby
Journal:  Intensive Care Med       Date:  2010-04-16       Impact factor: 17.440

Review 3.  Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects.

Authors:  Garyphallia Poulakou; Dimitrios K Matthaiou; David P Nicolau; Georgios Siakallis; George Dimopoulos
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

4.  Year in review in Intensive Care Medicine 2010: II. Pneumonia and infections, cardiovascular and haemodynamics, organization, education, haematology, nutrition, ethics and miscellanea.

Authors:  Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2011-01-12       Impact factor: 17.440

5.  Year in review in Intensive Care Medicine 2009: II. Neurology, cardiovascular, experimental, pharmacology and sedation, communication and teaching.

Authors:  Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2010-01-28       Impact factor: 17.440

Review 6.  Nebulized Colistin in Ventilator-Associated Pneumonia and Tracheobronchitis: Historical Background, Pharmacokinetics and Perspectives.

Authors:  Yinggang Zhu; Antoine Monsel; Jason A Roberts; Konstantinos Pontikis; Olivier Mimoz; Jordi Rello; Jieming Qu; Jean-Jacques Rouby
Journal:  Microorganisms       Date:  2021-05-27

7.  Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial.

Authors:  Sami Abdellatif; Ahlem Trifi; Foued Daly; Khaoula Mahjoub; Rochdi Nasri; Salah Ben Lakhal
Journal:  Ann Intensive Care       Date:  2016-03-31       Impact factor: 6.925

8.  Aerosol delivery with two ventilation modes during mechanical ventilation: a randomized study.

Authors:  Jonathan Dugernier; Gregory Reychler; Xavier Wittebole; Jean Roeseler; Virginie Depoortere; Thierry Sottiaux; Jean-Bernard Michotte; Rita Vanbever; Thierry Dugernier; Pierre Goffette; Marie-Agnes Docquier; Christian Raftopoulos; Philippe Hantson; François Jamar; Pierre-François Laterre
Journal:  Ann Intensive Care       Date:  2016-07-22       Impact factor: 6.925

Review 9.  The use of inhaled antibiotic therapy in the treatment of ventilator-associated pneumonia and tracheobronchitis: a systematic review.

Authors:  Christopher J Russell; Mark S Shiroishi; Elizabeth Siantz; Brian W Wu; Cecilia M Patino
Journal:  BMC Pulm Med       Date:  2016-03-08       Impact factor: 3.317

Review 10.  Nebulized antibiotics in mechanically ventilated patients: a challenge for translational research from technology to clinical care.

Authors:  Stephan Ehrmann; Jean Chastre; Patrice Diot; Qin Lu
Journal:  Ann Intensive Care       Date:  2017-08-01       Impact factor: 6.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.